A survey on the management of new onset atrial fibrillation in critically ill patients with septic shock.

Competing Interests: Declaration of Competing Interest AC received research grant from RESICARD; and consultant/advisory board fees from Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Novartis, and Pfizer, unrelated with the present study. GV received research grant from BioMérieux, SOS Oxygène, Janssen; and advisory board fees from BioMérieux unrelated with the present study. VL receives advisory board fees from Amomed unrelated with the present study. AMD reports research grants from Fischer Paykel, Baxter, Philips, Ferring and GSK; participation to advisory board for Air Liquide, Baxter, and Amomed, lectures for Getingue and Addmedica, unrelated to the present study. FB and MF declared no relevant conflict of interest.